Patents Represented by Attorney, Agent or Law Firm Incyte Pharmaceuticals, Inc.
-
Patent number: 6132964Abstract: The invention provides human hydrolase-like molecules (HHLM) and polynucleotides which identify and encode HHLM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HHLM.Type: GrantFiled: February 6, 1998Date of Patent: October 17, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Preeti Lal, Jennifer L. Hillman, Neil C. Corley, Karl J. Guegler, Purvi Shah
-
Patent number: 6130064Abstract: The invention provides a human SMN-like protein (HSLP) and polynucleotides which identify and encode HSLP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HSLP.Type: GrantFiled: February 24, 1998Date of Patent: October 10, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Y. Tom Tang, Neil C. Corley, Karl J. Guegler
-
Patent number: 6130039Abstract: The invention provides a human lysyl hydroxylase-like protein (HLHLP) and polynucleotides which identify and encode HLHLP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HLHLP.Type: GrantFiled: December 12, 1997Date of Patent: October 10, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Purvi Shah, Preeti Lal, Neil C. Corley
-
Patent number: 6130325Abstract: The present invention provides two human p24 vesicle trafficking proteins (designated individually as Hp24-1 and Hp24-2 and collectively as Hp24) and polynucleotides which identify and encode Hp24. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding Hp24 and a method for producing Hp24. The invention also provides for agonists, antibodies, or antagonists specifically binding Hp24, and their use, in the prevention and treatment of diseases associated with expression of Hp24. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding Hp24 for the treatment of diseases associated with the expression of Hp24. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding Hp24.Type: GrantFiled: February 14, 1997Date of Patent: October 10, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Surya K. Goli, Olga Bandman
-
Patent number: 6130077Abstract: The invention provides a human cytochrome P450 (HUCYP) and polynucleotides which identify and encode HUCYP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HUCYP.Type: GrantFiled: October 1, 1998Date of Patent: October 10, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Henry Yue, Karl J. Guegler, Neil C. Corley, Janice Au-Young
-
Patent number: 6127146Abstract: The invention provides a human fibrous protein (FIBR) and polynucleotides which identify and encode FIBR. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of FIBR.Type: GrantFiled: March 3, 1998Date of Patent: October 3, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Karl J. Guegler, Neil C. Corley
-
Patent number: 6124123Abstract: The present invention provides a human ubiquitin-conjugating enzyme (UBCPB) and polynucleotides which identify and encode UBCPB. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding UBCPB and a method for producing UBCPB. The invention also provides for agonists, antibodies, or antagonists specifically binding UBCPB, and their use, in the prevention and treatment of diseases associated with expression of UBCPB. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding UBCPB for the treatment of diseases associated with the expression of UBCPB. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding UBCPB.Type: GrantFiled: August 12, 1998Date of Patent: September 26, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Surya K. Goli
-
Patent number: 6124116Abstract: The present invention provides four human Rab and Rab-associated proteins (designated collectively as HRAB) and polynucleotides which identify and encode HRAB. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HRAB and a method for producing HRAB. The invention also provides for use of HRAB and agonists, antibodies, or antagonists specifically binding HRAB, in the prevention and treatment of diseases associated with expression of HRAB. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HRAB for the treatment of diseases associated with the expression of HRAB. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HRAB.Type: GrantFiled: October 29, 1996Date of Patent: September 26, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Janice Au-Young
-
Patent number: 6124446Abstract: The invention provides a human Vps35/Mem3-related protein (hvmrp) and polynucleotides which identify and encode hvmrp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of hvmrp.Type: GrantFiled: January 8, 1998Date of Patent: September 26, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Neil C. Corley, Purvi Shah
-
Patent number: 6124095Abstract: The invention provides a human nucleotide pyrophosphohydrolase-2 (NTPPH-2) and polynucleotides which identify and encode NTPPH-2. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of NTPPH-2.Type: GrantFiled: December 22, 1997Date of Patent: September 26, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Holly Magna, Paul Schaffer, Michael Lawton, Sue Yocum, Peter Mitchell, Nancy Hutchinson, Lynn E. Murry
-
Patent number: 6121019Abstract: The invention provides three human cell division regulators (HCDR) and polynucleotides which identify and encode HCDR. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for preventing and treating disorders associated with expression of HCDR.Type: GrantFiled: March 23, 1999Date of Patent: September 19, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Olga Bandman, Preeti Lal, Purvi Shah, Neil C. Corley
-
Patent number: 6117989Abstract: The invention provides human calcium-binding proteins (CaBPs) and polynucleotides which identify and encode CaBP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of CaBP.Type: GrantFiled: March 26, 1998Date of Patent: September 12, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Jennifer L. Hillman, Neil C. Corley, Karl J. Guegler, Preeti Lal, Chandra Patterson
-
Patent number: 6113904Abstract: The present invention provides polynucleotides which identify and encode a novel human glycoprotein (SC2H). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding SC2H. The invention also provides for the use of substantially purified SC2H and its agonists in the commercial production of recombinant proteins for the treatment of diseases associated with the expression of SC2H. Additionally, the invention provides for the use of antisense molecules to SC2H in the treatment of diseases associated with the expression of SC2H. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotides which hybridize with naturally occurring sequences encoding SC2H and antibodies which specifically bind to the protein.Type: GrantFiled: April 20, 1998Date of Patent: September 5, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Janice Au-Young, Phillip R. Hawkins, Jennifer L. Hillman
-
Patent number: 6114123Abstract: The invention provide a mammalian nucleic acid molecule and fragments thereof. It also provides for the use of the mammalian nucleic acid molecule for the characterization, diagnosis, evaluation, treatment, or prevention of conditions, diseases and disorders associated with gene expression and for the production of a model system. The invention additionally provides expression vectors and host cells for the production of the protein encoded by the mammalian nucleic acid molecule.Type: GrantFiled: June 14, 1999Date of Patent: September 5, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Lynn E. Murry, Tom Y. Tang, Mariah R. Baughn
-
Patent number: 6110686Abstract: The present invention provides a human cystatin-like protein (CSTIN) and polynucleotides which identify and encode CSTIN. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding CSTIN and a method for producing CSTIN. The invention also provides for agonists, antibodies, or antagonists specifically binding CSTIN, and their use, in the prevention and treatment of diseases associated with expression of CSTIN. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding CSTIN for the treatment of diseases associated with the expression of CSTIN. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding CSTIN.Type: GrantFiled: May 19, 1999Date of Patent: August 29, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Surya K. Goli
-
Patent number: 6110722Abstract: The present invention provides a human ATP synthase subunit (ASYS) and polynucleotides which encode ASYS. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provides methods for producing ASYS and for treating disorders associated with expression of ASYS.Type: GrantFiled: April 24, 1998Date of Patent: August 29, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Patent number: 6103471Abstract: The invention provides a human beta-alanine-pyruvate aminotransferase (HAPA) and polynucleotides which identify and encode HAPA. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HAPA.Type: GrantFiled: January 29, 1998Date of Patent: August 15, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Preeti Lal, Neil C. Corley
-
Patent number: 6103874Abstract: The present invention provides a novel human KDEL receptor (NHKR) and polynucleotides which identify and encode NHKR. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NHKR and a method for producing NHKR. The invention also provides for agonists, antibodies, or antagonists specifically binding NHKR, and their use, in the prevention and treatment of diseases associated with expression of NHKR. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding NHKR for the treatment of diseases associated with the expression of NHKR. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding NHKR.Type: GrantFiled: August 13, 1998Date of Patent: August 15, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Jennifer L. Hillman, Surya K. Goli
-
Patent number: 6103469Abstract: The invention provides a human phospholipase A2 protein PHPLA2 and polynucleotides which identify and encode PHPLA2. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of PHPLA2.Type: GrantFiled: November 7, 1997Date of Patent: August 15, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Phillip R. Hawkins, Olga Bandman, Karl J. Guegler, Purvi Shah, Neil C. Corley
-
Patent number: 6103477Abstract: The present invention provides a human Rho protein (HRHO) and polynucleotides which identify and encode HRHO. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention provides methods for producing HRHO and for treating or preventing disorders associated with expression of HRHO.Type: GrantFiled: October 12, 1999Date of Patent: August 15, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli